Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 GNPX | Healthcare | $2.08 | 11.53K | $1.81M | -0.04 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GNPX | Genprex | 2.08 | -95.38 | -97.87% |
| Name | Price | % Change | |
|---|---|---|---|
| GNPX | $2.08 | -97.87% |
Genprex (GNPX) announced results from a translational analysis of patients treated with its lead drug candidate, Reqorsa – quaratusugene ozeplasmid -, a gene therapy product. The data suggest that increased
An announcement from Genprex ( ($GNPX) ) is now available. On November 5, 2026, Genprex announced translational analysis results from 11 lung cancer patients treated with Reqorsa in two clinical
Genprex ( ($GNPX) ) has shared an update. On November 4, 2026, Genprex announced research indicating that TROP2 expression could serve as a predictive biomarker for response to Reqorsa in
Genprex ( ($GNPX) ) has provided an update. On October 28, 2026, Genprex announced that research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological
Genprex ( ($GNPX) ) has issued an update. On October 21, 2026, Genprex highlighted new peer-reviewed research in mice underscoring a key role for the TUSC2 tumor suppressor gene in
Genprex (GNPX) highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader
Genprex ( ($GNPX) ) just unveiled an announcement. On August 18, 2026, Genprex announced a development and manufacturing agreement with a leading U.S. CDMO to scale up manufacturing of its
Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufacturing Organization, or CDMO, to initiate the manufacturing scale-up of
An update from Genprex ( ($GNPX) ) is now available. On July 29, 2026, a Nasdaq Hearings Panel granted Genprex an exception to continue its listing while it worked to
Genprex ( ($GNPX) ) has issued an update. On August 3, 2026, Genprex announced a collaboration with Roche Diagnostics to validate biomarkers, notably TROP2 and PTEN, for selecting non-small cell
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
